GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noile-Immune Biotech Inc (TSE:4893) » Definitions » Asset Impairment Charge

Noile-Immune Biotech (TSE:4893) Asset Impairment Charge : 円0.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Noile-Immune Biotech Asset Impairment Charge?

Noile-Immune Biotech's Asset Impairment Charge for the three months ended in Mar. 2024 was 円0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was 円0.0 Mil.


Noile-Immune Biotech Asset Impairment Charge Historical Data

The historical data trend for Noile-Immune Biotech's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noile-Immune Biotech Asset Impairment Charge Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Asset Impairment Charge
- - - -

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only - - - - -

Noile-Immune Biotech Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.0 Mil.


Noile-Immune Biotech Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Noile-Immune Biotech's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.


Noile-Immune Biotech (TSE:4893) Business Description

Traded in Other Exchanges
N/A
Address
2-12-10 Shiba-Daimon, Minato-ku, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of novel cancer immunotherapy including CAR-T cell therapy.

Noile-Immune Biotech (TSE:4893) Headlines

No Headlines